Skip to main content
Premium Trial:

Request an Annual Quote

Biosift Acquires Entigen s Technology Assets

NEW YORK, March 24 - Cambridge, Mass.-based bioinformatics firm Biosift said today that it has acquired Entigen's intellectual property and technology assets, which have been in a state of suspension since Entigen closed its offices last March.

 

Biosift purchased rights to Entigen's BioNavigator genomics portal and Adaapt data integration technology. These tools will be integrated with Biosift's Radia sequence analysis package and Scintilla genome browser.

 

Entigen was formed in December 2000 by the merger of bioinformatics ASP eBioinformatics and integration technology provider Empatheon. It maintained offices in Sydney, Australia, and Sunnyvale, Calif., before shutting its doors a year ago following an unsuccessful attempt to raise additional funding.

 

Bala Manian, chairman of the board at Entigen, told GenomeWeb.com's sister publication BioInform last April that the company's tools and assets were "being held in abeyance" while he sought a buyer for the technology.

 

"The company's not closed down," he said at the time, noting that he hoped to sell the technology in one piece rather than split it between several buyers.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.